Ainscow, COO of ASP Isotopes, sells $71944 in ASPI stock

Published 11/09/2025, 02:06
Ainscow, COO of ASP Isotopes, sells $71944 in ASPI stock

Robert Ainscow, Chief Operating Officer of ASP Isotopes Inc (NASDAQ:ASPI), sold 8,438 shares of common stock on September 8, 2025, for a total of $71944. The shares were sold at a price of $8.5263, close to the current trading price of $8.37. The stock has shown remarkable performance, delivering a 232% return over the past year, though InvestingPro analysis indicates the stock is slightly overvalued at current levels.

On September 9, 2025, Ainscow also exercised options to acquire 150,000 shares at $0.25, 12,000 shares at $2.00 and 135,000 shares at $2.00, for a total of $331500.

On the same day, Ainscow disposed of 4,396 shares, 2,813 shares and 31,652 shares for $331484. The price per share was $8.53.

Following these transactions, Ainscow directly owns 1,669,693 shares of ASP Isotopes Inc, representing a significant stake in the company, which currently has a market capitalization of $781 million.

In other recent news, ASP Isotopes Inc. has been involved in several significant developments. The company announced a Memorandum of Understanding with Fermi America to explore the development of a High Assay Low Enriched Uranium (HALEU) enrichment facility in Carson County, Texas. This planned facility aims to enhance domestic nuclear fuel production and reduce reliance on Russian sources. Additionally, ASP Isotopes and its subsidiary, Quantum Leap Energy LLC, are set to form a joint venture with Fermi America to produce HALEU for small modular reactors at the HyperGrid campus near Amarillo, Texas. In corporate governance, Ralph L. Hunter has joined the ASP Isotopes board of directors and the board of managers of Quantum Leap Energy LLC, bringing over 30 years of nuclear industry experience. Furthermore, ASP Isotopes has invested $5 million in seed funding into IsoBio, Inc., supporting their development of antibody-isotope conjugates for cancer treatment. These recent developments underscore ASP Isotopes’ strategic initiatives in both nuclear fuel production and medical isotope technology.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.